American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed but generally positive outlook. Despite a revenue guidance cut, the company shows strong cost containment and improving margins, with a significant GAAP gross margin increase. The Q&A highlights strategic wins like the Florida Blues plan, divestiture focus, and AI's role in efficiency, all suggesting positive market sentiment. The EBITDA loss improvement and cash position are reassuring, while the lack of detailed guidance on AI's financial impact is a minor concern. Overall, the strategic focus and financial health indicators suggest a positive stock reaction.
Key Financial Performance
Total Revenue $56.3 million, an 8% decrease year-over-year. The decrease includes the step-down in contribution from Leidos and the divestiture of APC. Normalizing for the sale of APC, Q3 revenue would have increased 1.3%.
Subscription Revenue $30.9 million, an 18% increase year-over-year. This represented 55% of total revenue compared to 43% a year ago.
Total Visit Volume Approximately 1.1 million visits, down 21% year-over-year. Normalizing for the sale of APC, visits were down 3.5%.
AMG Visit Revenue $21.2 million, 23% lower than last year. Normalizing for the sale of APC, visits were down 3.5%.
Average Revenue Per Visit $71, 14% lower compared to last year's Q3. Normalizing for the sale of APC, average revenue per visit was 3.5% higher, driven by a continued mix shift to higher-priced virtual primary care and specialty care visits.
GAAP Gross Margin 52%, compared to 37% a year ago. The increase was due to greater software and services revenue generating stronger margin contribution and the divestiture of APC.
Operating Expenses $58.9 million, a decrease of 16% compared to last year. This includes a 6% reduction in R&D, a 46% decrease in sales and marketing, and a 14% decrease in G&A expenses.
Adjusted EBITDA A loss of $12.7 million, compared favorably to a loss of $31 million a year ago. This reflects the execution of cost containment initiatives.
Cash Burn Approximately $18 million in Q3. The company ended the quarter with approximately $201 million in cash and marketable securities with 0 debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Amwell Platform: Focused on creating the most effective and valuable hybrid care backbone, integrating AI into core workflows, enhancing program integration, and investing in data and analytics infrastructure.
AI Integration: Enterprise-grade AI is being implemented to transform patient intake, personalized dialogue, navigation, and clinical program matching.
Clinical Program Integration: Enhanced integration with third-party and Amwell's own clinical programs, offering more options across the care continuum.
Market Demand for Digital Health: Consumer demand for digital health is accelerating, with mental health telehealth utilization reaching 27.8% and 79% of Gen Z using health technology monthly.
Fragmentation Challenges: Payers, employers, and health systems face challenges with fragmented solutions, creating opportunities for Amwell's integrated platform.
Cost Efficiencies: Achieved meaningful cost efficiencies through restructuring, reducing R&D, sales, marketing, and G&A expenses.
Divestiture of Non-Core Assets: Sold Amwell Psychiatric Care (APC) and pursuing other divestitures to focus on core operations.
AI Adoption for Efficiency: Widespread AI adoption and talent reallocation have improved operational efficiency.
Focus on Core Operations: Decisively divesting non-core assets and focusing on core offerings to align with customer needs.
Positioning as Integrated Solution Provider: Amwell is positioning itself as a long-term partner offering a unified, flexible, and scalable platform to address fragmentation in healthcare solutions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Shifts and Consumer Demand: While consumer demand for digital health is accelerating, the market is also experiencing fragmentation. Employers manage multiple point solutions, leading to inefficiencies and high costs, such as $20 million annually due to inefficient data exchange. This fragmentation poses challenges for Amwell to position itself as a unified solution.
Operational Efficiency and Cost Management: Amwell is undergoing restructuring, including divesting non-core assets and rightsizing headcount. While these measures aim to improve efficiency, they also carry risks of operational disruptions and potential loss of talent.
Revenue and Visit Volume Decline: Total revenue decreased by 8% year-over-year, and visit volume dropped by 21%. Although some of this is attributed to the sale of APC, the decline in visit volume and revenue per visit could impact financial stability.
Integration and Technology Challenges: Amwell's strategy heavily relies on integrating AI and other technologies into its platform. The success of this integration is critical, and any delays or failures could hinder operational and strategic goals.
Competitive Pressures: The market for digital health solutions is highly competitive, with significant investment in AI startups capturing 60% of digital health funding. Amwell faces pressure to differentiate its offerings and maintain its market position.
Economic and Regulatory Uncertainties: Economic conditions and regulatory changes could impact Amwell's operations and financial performance, especially as it aims to achieve cash flow breakeven by 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cash Flow Breakeven: The company aims to achieve cash flow breakeven by the end of 2026 and resume profitable growth.
AI Integration: Amwell is moving AI into the core workflow layer to transform patient intake, personalized dialogue, navigation, and clinical program matching. This is expected to improve operational efficiency and patient outcomes.
Platform Enhancements: The company is enhancing its platform to simplify integration with third-party clinical programs and improve data and analytics infrastructure. This is aimed at offering better financial and clinical outcomes for customers.
Cost Structure Optimization: Amwell is rightsizing its cost structure, including reducing R&D expenses by over 10%, sales and marketing costs by more than 25%, and G&A expenses by at least 20% year-over-year in 2025.
Revenue Guidance for 2025: Full-year revenue is projected to be between $245 million and $248 million, with Q4 revenue expected to range from $51 million to $54 million.
Adjusted EBITDA Guidance: Adjusted EBITDA for 2025 is expected to range from negative $45 million to negative $42 million, with Q4 adjusted EBITDA projected between negative $15 million and negative $12 million.
Market Trends: Consumer demand for digital health is accelerating, with significant adoption among Gen Z and increasing utilization of mental health telehealth services. Integration of digital solutions is a top priority for health plan leaders.
Strategic Focus Areas: Amwell is focusing on hybrid care solutions, AI-driven automation, and integration of digital therapeutic solutions to address market fragmentation and improve customer outcomes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How did Amwell secure the Florida Blues plan win, and are there similar opportunities in the future?
A:Amwell won the Florida Blues plan in a competitive situation by deinstalling a major competitor. The win was driven by the need for a unified infrastructure to address fragmentation and vendor fatigue, enabling efficient consumer engagement and integration of AI-driven programs. This win is indicative of future demand for similar solutions.
Q:What insights can you provide about potential divestiture of noncore assets?
A:The divestiture of noncore assets is a practical strategy to focus on high ROI opportunities like the Florida Blue initiative. Legacy products, such as automated programs for hospitals, will receive less investment. The company is actively implementing this strategy to align with its focus on core offerings.
Q:How does Amwell plan to monetize AI and its impact on financial performance?
A:AI influences Amwell's ecosystem by enhancing clinical programs, personalizing consumer experiences, and improving data analytics. While AI-driven features are not directly charged, they increase ROI for customers and platform traction. Revenue is generated through partnerships, such as rev share with companies like Sword. AI also improves operational efficiency, contributing to better financial and clinical outcomes.
Q:What is the impact of AI features on margins and financial outlook for 2026?
A:AI features are not expected to significantly impact margins. Margin variations will depend on the mix of software revenues and implementation revenues. The margin profile for 2026 is expected to be consistent with 2025.
Q:Are there additional noncore assets to divest, and what is the timing?
A:There are a few defined noncore assets that can be divested without affecting client focus. The timing is flexible and depends on obtaining good value for these assets. The company aims to narrow its focus throughout 2026.
Q:How has the macroeconomic environment affected Amwell's sales pipeline and direct tariff exposure?
A:The macroeconomic environment has not significantly impacted Amwell's sales pipeline for core offerings, as they address essential pain points for customers. However, there is resistance in areas like workflow automation and inpatient solutions. Direct tariff exposure is minimal, with negligible impact on performance.
Q:What is the impact of diverting resources from noncore assets on guidance and cash flow breakeven?
A:Diverting resources from noncore assets is not included in the current guidance and is not expected to substantially impact the cash flow breakeven target for 2026.
Q:Are current operating expense levels sustainable, and is there room for further optimization?
A:Current operating expense levels are sustainable, with opportunities for further cost reductions in G&A and delivery functions. AI tools are expected to enhance efficiency and scalability, particularly in clinical operations.
Q:What factors are prioritized to achieve the cash flow breakeven target for 2026?
A:Client retention is the top priority, followed by growth initiatives on the product side. Divesting noncore assets will help focus on core initiatives and strengthen the balance sheet.
Q:Are there areas where Amwell prefers to own solutions outright rather than partner with third parties?
A:Amwell focuses on integrating third-party solutions under its platform to meet customer needs. The company is open to implementing any compliant and secure solutions chosen by its customers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the timing and value of noncore asset divestitures, as well as the exact financial impact of AI-driven features on margins and cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APC visit
Bank Research
COO CFO
Consumer
Division Truist
Division UBS
Executive VP
Inc Research
Investment Bank
LLC Research
Research Division
Securities Inc
Truist Securities
UBS Investment
VP COO
action
adoption
asset
client program
decrease
divestiture APC
effectiveness
employer health
enterprise grade
exchange
grade AI
integration
intervention
member engagement
outcome
party partner
payer employer
plan
reduction RD
resource
sale APC
survey
tool
work stream
AMWL Transcript
American Well Corporation (AMWL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call lacked detailed financial information and updates on operational performance, making it difficult to gauge the company's current state. The focus on platform development and addressing customer needs is positive, but concerns about regulatory hurdles and strategic execution risks introduce uncertainties. The absence of explicit financial metrics or shareholder return plans further limits positive sentiment. Overall, the lack of critical financial details and mixed strategic signals suggest a neutral outlook.
American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
Unknown2-13
The earnings call reveals significant declines in revenue, subscription, and visit metrics, alongside reduced gross profit and margin pressure. Despite improved operating expenses and EBITDA, the lack of clear guidance on DHA renewal and AI integration impact, coupled with unclear management responses, heightens uncertainty. The Q&A section suggests optimism but lacks concrete data, and the 2026 guidance presents both headwinds and tailwinds. The absence of a market cap limits precise prediction, but overall sentiment leans negative due to financial declines and uncertainty in strategic renewals.
CAVA Group, Inc. (CAVA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture: while there are positive elements such as improved subscription revenue and cost reduction initiatives, the revised revenue guidance and negative EBITDA projections temper the outlook. The Q&A section highlights concerns about operational challenges and macroeconomic pressures, which, along with unclear management responses, suggest cautious investor sentiment. The overall sentiment is neutral, as the positive and negative factors seem to balance each other out.
American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a mixed but generally positive outlook. Despite a revenue guidance cut, the company shows strong cost containment and improving margins, with a significant GAAP gross margin increase. The Q&A highlights strategic wins like the Florida Blues plan, divestiture focus, and AI's role in efficiency, all suggesting positive market sentiment. The EBITDA loss improvement and cash position are reassuring, while the lack of detailed guidance on AI's financial impact is a minor concern. Overall, the strategic focus and financial health indicators suggest a positive stock reaction.
AMWL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
